Colorectal Cancer | Specialty

The colorectal cancer condition center is a comprehensive resource for clinical news and expert insights on colorectal cancer. Read more at OncLive.

FDA to Hold End-of-Phase 2 Meeting for Botensilimab Plus Balstilimab in R/R mCRC

May 16th 2024

The FDA will hold an end-of-phase 2 meeting to discuss botensilimab plus balstilimab for the treatment of patients with relapsed/refractory metastatic colorectal cancer.

Dr Pederson on Novel Therapies for the Management of Targetable mCRC

May 13th 2024

Katrina S. Pedersen, MD, MS, discusses key updates in the therapeutic landscape for patients with molecularly targetable metastatic colorectal cancer.

Advances in MRD Testing Help Guide Optimal Colorectal Cancer Therapy

May 10th 2024

During an OncLive Peer Exchange, a panel of expert clinicians in CRC discussed studies seeking to further define the role of MRD testing in CRC.

Unmet Needs and Future Perspectives in Colorectal Cancer

May 9th 2024

The panel concludes with perspectives on the future of treatment for patients with colorectal cancer, including unmet needs in the disease space.

FDA Approves Noninvasive Stool RNA Screening Test for CRC

May 7th 2024

The FDA has approved ColoSense for use as a screening test in adults 45 years of age or older who are at average risk of developing colorectal cancer.

Dr Lenz on the Association Between HER2 Expression and Treatment Outcomes in mCRC

May 6th 2024

Heinz-Josef Lenz, MD, FACP, discusses the association between HER2 expression and treatment outcomes in metastatic colorectal cancer.

Trajectory of CRC Treatment Landscape

May 6th 2024

The panelists provide their final thoughts, exploring the prospective treatment landscape for patients with CRC.

EMA Validates MAA for Frontline Nivolumab/Ipilimumab for MSI-H/dMMR mCRC

May 6th 2024

The European Medicines Agency has validated an application for nivolumab plus ipilimumab for frontline MSI-H/dMMR metastatic colorectal cancer.

MRD Testing in CRC: Gaps in our Understanding and Potential Advancements

May 6th 2024

The expert panel continues the discussion with thoughts on gaps in our understanding and application of MRD testing for colorectal cancer and a look to the future, highlighting potential advancements.

Multidisciplinary Care for Patients with CRC

May 2nd 2024

Clinical insights on the roles of various members within a multidisciplinary team involved in the care of patients with colorectal cancer.

Toxicity Considerations and Treatment Decisions in CRC

May 2nd 2024

Experts on colorectal cancer discuss the treatment decision-making process, highlighting the safety profiles of fruquintinib and regorafenib.

Dr Kopetz on the Future Utility of Adagrasib/Cetuximab in KRAS G12C–Mutant CRC

April 30th 2024

Scott Kopetz, MD, PhD, FACP, discusses the potential FDA approval of adagrasib in combination with cetuximab in KRAS G12C-mutatated colorectal cancer.

CIRCULATE-NORTH AMERICA and Barriers to Enrollment

April 29th 2024

Stacey Cohen, MD, discusses the rationale and study design of the phase 2/3 CIRCULATE-NORTH AMERICA study evaluating adjuvant chemotherapy selection based on MRD, and the panel discusses barriers to enrollment.

Recent Data from INTERCEPT and COSMOS-CRC-01 in Colorectal Cancer: Part 2

April 29th 2024

The panel continues its review of data presented on MRD testing in colorectal cancer from the INTERCEPT and COSMOS-CRC-01 studies.

Dr Kopetz on the Background of the KRYSTAL-1 Trial in KRAS G12C+ mCRC

April 26th 2024

Scott Kopetz, MD, PhD, FACP, discusses using adagrasib plus cetuximab in patients with metastatic colorectal cancer harboring KRAS G12C mutations.

Fruquintinib Receives Positive CHMP Opinion for Previously Treated mCRC

April 26th 2024

CHMP has voiced its support for the approval of fruquintinib in previously treated metastatic colorectal cancer.

Next-Generation ColoAlert Screening Test Shows High Sensitivity, Specificity for CRC and Adenoma Detection

April 25th 2024

Topline findings with the next-generation ColoAlert® test demonstrated 92% sensitivity and 90% specificity rates for colorectal cancer detection.

Retrospective Data Show Association Between HER2 Expression and Survival Outcomes in mCRC

April 25th 2024

HER2 gene expression is associated with prognostic and predictive value in patients with metastatic colorectal cancer.

HER2 Expression May Hold the Key to Predicting Survival Outcomes in CRC

April 24th 2024

Heinz-Josef Lenz, MD, FACP, discusses the prognostic and predictive value of HER2 expression levels in select patients with colorectal cancer.

Recent Data from INTERCEPT and COSMOS-CRC-01 in Colorectal Cancer

April 23rd 2024

The panel reviews recent data on MRD testing in colorectal cancer, highlighting the INTERCEPT and COSMOS-CRC-01 studies.